13G Filing: Partner Fund Management and Coherus Biosciences Inc. (CHRS)

Page 2 of 13

Page 2 of 13 – SEC Filing

CUSIP No. 19249H103 13G Page 2 of 13 Pages

1.

NAME OF REPORTING PERSON

S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Partner Fund Management, L.P.

2.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a)     ¨

(b)     x

3.

SEC USE ONLY

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

NUMBER OF

SHARES

BENEFICIALLY

OWNED BY

EACH

REPORTING

PERSON

WITH

5.

SOLE VOTING POWER

0

6.

SHARED VOTING POWER

 

1,600,863 shares

7.

SOLE DISPOSITIVE POWER

0

8.

SHARED DISPOSITIVE POWER

See Row 6 above

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

See Row 6 above

10.

CHECK
BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES                              ¨

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

3.1%1

 

12.

TYPE OF REPORTING PERSON

IA; PN


1 The percentages reported in this Schedule 13G are based upon approximately 51,288,117 shares of common
stock outstanding as of April 28, 2017 according Form 10-Q filed by the issuer with the Securities and Exchange Commission on May
8, 2017. All of the other numbers and percentages reported in this Schedule 13G are as of 9:00 a.m. (ET) on the date of filing.

Follow Coherus Biosciences Inc. (NASDAQ:CHRS)




Page 2 of 13